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Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-activated transcription factor and a member of the nuclear
receptor superfamily. PPARγ and its ligands appear to serve diverse biological functions. In addition to the well-studied eﬀects
of PPARγ on metabolism and cellular diﬀerentiation, abundant evidence suggests that PPARγ is an important regulator of the
immune system and cancers. Since cytokines are not only key modulators of inﬂammation with pro- and anti-inﬂammatory
functions but they also can either stimulate or inhibit tumor growth and progression, this review summarizes the role for PPARγ
in the regulation of cytokine production and cytokine-mediated signal transduction pathways in immune cells and cancer.
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1. INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) are
members of the nuclear receptor superfamily [1–6]. PPARs
exist in three isoforms, PPARα,P P A R β/δ,a n dP P A R γ,w h i c h
are encoded by diﬀerent genes and harbour isotype-speciﬁc
expression patterns and functions. PPARs were initially
identiﬁed as mediators of peroxisome proliferation in rodent
liver, where PPARα plays the major role. However, none of
the PPARs could be attributed to peroxisome proliferation
in humans [7–10] .A m o n gt h ev a r i o u ss u b t y p e so fP P A R s ,
PPARγ is the best characterized receptor in humans. There
are at least two PPARγ isoforms derived from the alternative
promoters, PPARγ1a n dP P A R γ2. PPARγ2 isoform is longer
than PPARγ1 by additional 30 N-terminal amino acids
[11, 12]. Synthetic ligands including the thiazolidinedione
(TZD) class of drugs, L-tyrosine-based compounds, and
diindolymethanes as well as natural ligands including a
broad range of polyunsaturated fatty acids 9- and 13-
hydroxyoctadecadienoic acid (9- and 13-HODE) and the
eicosanoids 15-deoxy-Δ12,14-prostaglandin J2 (15-d-PGJ2)
function as eﬃcacious PPARγ activators [13–15].
PPARγ is expressed at high levels in adipose tissue and
is an important regulator of adipocyte diﬀerentiation, which
functions as a ligand-dependent, sequence-speciﬁc activator
of transcription. Expression of PPARγ in immune system
was initially documented in 1994. Kliewer et al. reported
that PPARγ is expressed at high levels in mouse spleen [8].
Greene et al. detected the expression of PPARγ2i nn o r m a l
neutrophils and peripheral blood lymphocytes by Northern
blot analysis in 1995 [9]. Monocytes and macrophages were
the ﬁrst cells of the immune system in which the physical
presence and anti-inﬂammatory properties of PPARs were
ﬁrst described [16, 17]. Subsequently, PPARγ has been
reportedtoexistinotherimmunecelltypesofhematopoietic
origin, including T lymphocytes [18–22], B lymphocytes
[23], NK cells [24], dendritic cells [25–28], eosinophils [29],
and mast cells [30–32].
Multiple lines of evidence suggest that PPARs, especially
PPARγ, are known to be expressed or overexpressed in
several cancers such as epithelial tumor cells, renal cell
carcinoma cells, myeloid and lymphoid malignancies, and
multiple myeloma cells [33–37]. Ligands of PPARγ have
been shown to promote diﬀerentiation and to inhibit cell
growth and induce apoptosis in several types of human
cancer, including colon cancer [38–40], breast cancer [41,
42], lung cancer [43], prostate cancer [44, 45], gastric
cancer [46], liposarcoma [47, 48], and leukaemia [49],2 PPAR Research
supporting a role for PPARγ ligands as potential tumor
suppressors in PPARγ-dependent or -independent manner
[50, 51], although several murine models suggest that, under
certain circumstances, PPARγ ligands may stimulate cancer
formation [36].
The cytokines are a large family of secreted molecules
consisting of more than 100 peptides or glycoproteins. Each
cytokine is secreted by particular cell types in response to a
variety of stimuli and produces a characteristic constellation
of eﬀects on the growth, motility, diﬀerentiation, or function
ofitstargetcells.Cytokinescanactinanautocrinemannerto
aﬀectthebehaviorofthecellthatreleasesthecytokineand/or
in a paracrine manner to aﬀect the behavior of adjacent
cells. Moreover, some cytokines are stable enough to act
in an endocrine manner to aﬀect the behavior of distant
cells, although this depends on their abilities to enter the
circulation and their half-life in the blood. Cytokines are
especially important for regulating immune and inﬂamma-
tory responses with pro- and anti-inﬂammatory functions,
and have crucial functions in controlling both the innate
and adaptive arms of the immune response. Not only
do cytokines govern the development and homeostasis of
lymphocytes,buttheyalsodirectthediﬀerentiationofhelper
T cells and promote the generation of memory cells [52].
During formation anddevelopment oftumor, themixture of
cytokines that is produced in the tumor microenvironment
has an important role in cancer pathogenesis. Cytokines can
either stimulate or inhibit tumor growth and progression
[53–57]. Speciﬁc polymorphisms in cytokine genes are asso-
ciated with an increased risk of cancer [58]. Cytokines are
producedbyimmunecellsasahostresponsetocellularstress
caused by either exogenous or endogenous agents to control
and minimize cellular damage. However, an uncontrolled
and sustained generation of cytokines can lead to altered cell
growth, diﬀerentiation, and apoptosis. Therefore, cytokines
are a linker among immunity, inﬂammation, and cancer
[59].
In addition to their antiproliferative and proapoptotic
activities on immune cells and cancer cells, eﬀects of
PPARs and their ligands in immune system and cancer
cells may be mediated through inﬂuencing cytokine pro-
duction or cytokine-mediated signal transduction pathways.
Conversely, the expression of PPARs is also modulated
by cytokines. In this review, we recapitulate molecular
mechanisms on PPARs regulating cytokine production or
cytokine-mediated signal transduction and cell responses,
and enumerate their physiological and pathological conse-
quences in immune responses, inﬂammation, and cytokine-
responsive tumors.
2. MECHANISM(S) OF CYTOKINE GENE
REGULATION BY PPARγ
Like other nuclear receptors, the structure of PPARs is
comprised of: an amino-terminal activation function, AF-1
(A/B domain), which can activate transcription in a ligand-
independent fashion, the DNA-binding domain (DBD), a
hingeregion,andacarboxy-terminalligand-bindingdomain
(LBD) [1–3, 60, 61]. The DBD allows them to bind to and
activate target genes, thus deﬁning them as transcription
factors. The LBD also contains a second activation function
(AF-2) that maps to a surface-exposed hydrophobic pocket,
proving a docking site for coregulatory proteins, and mod-
ulates their activities, making them hormone-dependent
transcription factors. Upon ligand binding, PPARs het-
erodimerize with retinoid X receptors (RXRs) and form a
complex that translocates to the nucleus and regulates gene
expression.Thisheterodimericcomplexbindstoperoxisome
proliferator response elements (PPREs) located within the
promoter regions of target genes that consist of a direct
repetition of the consensus AGGTCA half-site spaced by
one or two nucleotides (DR1 or DR2). In addition to the
heterodimer complex, it has been reported that a host of
accessory proteins, named “coactivators” or “corepressors,”
bind to the nuclear receptors PPAR/RXR in a ligand-
dependent manner and impact the transcriptional process
by either remodeling chromatin structure and/or acting as
adapter molecules that link the nuclear receptor complex
to key transcriptional machinery. Ligand binding to PPARs
appears to trigger conformational changes that permit their
dissociation from corepressors and favor their association
with coactivators. The coactivators possess or recruit histone
acetyltransferase activity to the transcription site. Subse-
quently, acetylation of histone proteins alters chromatin
structure,therebyfacilitatingthebindingofRNApolymerase
and the initiation of transcription. In the absence of ligand,
PPARγ has the potential to silence genes to which it is
bound by recruiting transcriptional corepressor complexes
and repress gene expression [1–5, 62–64].
Surprisingly, most of the eﬀects of PPARs on cytokine
expression result from crosstalk with other transcriptional
factors through nongenomic transrepressive mechanisms.
It is well known that some key transcriptional factors
such as nuclear factor of activated T cells (NFAT), nuclear
factor-kappa B (NF-κB), GATA-3, T-bet, AP-1, or signal
transducers and activators of transcription (STAT) regulate
the expression of cytokine genes. Transrepression by PPARs
can occur either by inhibiting the binding of transcriptional
factorstoDNAthroughdirectproteintoproteininteractions
or by sequestrating cofactors necessary to their activity.
A protein-to-protein interaction between PPARs and other
transcription factors completely prevents these transcription
factors from binding to their own response elements and
therefore blocks their transcriptional activation of cytokine
genes [63, 64]. Activation of PPARγ negatively inﬂuences
the production of inﬂammatory cytokines such as tumor
necrosis factor-alpha (TNFα), Interleukin (IL)-6, and IL-
1β by macrophages. A well-established example is PPARγ
coassociation with NFAT, a T-cell speciﬁc transcription
f a c t o r ,i nr e g u l a t i o no fI L - 2g e n ee x p r e s s i o n[ 18]. The
transcription factor NFAT plays an essential role in gene
expression of IL-2 by T lymphocytes and is also involved in
the proliferation of peripheral T lymphocytes. Therefore, we
evaluated transcriptional activity and DNA binding of NFAT
to determine whether NFAT might be a target for negative
regulation of T-cell activation by PPARγ ligands. Utilizing
the gel-shift experiment, we found that PPARγ ligands
signiﬁcantly inhibited the speciﬁc binding of NFAT probeXiao Yi Yang et al. 3
corresponding to the human IL-2 promoter. The transcrip-
tional activation of the reporter construct directed by the
NFAT distal site of the IL-2 promoter was abrogated by 15-d-
PGJ2 orciglitazoneinthepresenceofPPARγ overexpression.
We further tested for complex formation between PPARγ
and NFAT in a coimmunoprecipitation experiment. The
NFAT can be coprecipitated with PPARγ in T cells induced
by PMA/PHA and 15-d-PGJ2 or ciglitazone. Furthermore,
the addition of anti-PPARγ antibody induced high-aﬃnity
binding of extracts to the NFAT probes as determined by
using an electronic mobility shift assay, demonstrating that
removal of PPARγ with this antiserum increases the target
speciﬁcity of NFAT. This data indicated that a direct physical
protein-protein interaction occurs between nuclear receptor
PPARγ and transcription factors NFAT, in turn inhibiting
transcription of IL-2 in T lymphocytes.
3. CROSSTALK OF PPARγ WITH CYTOKINE-MEDIATED
SIGNAL TRANSDUCTION PATHWAYS
Cytokines induce a variety of biological responses by binding
to speciﬁc cell surface receptors and activating cytoplasmic
signal transduction pathways, such as the Janus kinase-
signal transducer and activator of transcription (JAK-
STAT) pathway, which transmits information received from
extracellular polypeptide signals, through transmembrane
receptors, directly to target gene promoters in the nucleus,
providing a mechanism for transcriptional regulation with-
out second messengers [65–74]. JAKs bind speciﬁcally to
intracellular domains of cytokine receptor signaling chains
and catalyze ligand-induced phosphorylation of themselves
and of intracellular tyrosine residues on the receptor,
creating STAT docking sites. Phosphorylation of STATs
on activating tyrosine residues leads to STAT homo- and
heterodimerization. STAT dimers are rapidly transported
from the cytoplasm to the nucleus and are competent for
DNA binding. Binding of the activated STAT dimer to a
target promoter initials formation of a primary transcrip-
tion complex and dramatically increases the transcription
rate from this promoter of target gene. Transcription
of target genes induced by the STAT dimers reﬂects an
intrinsic ability of STAT transcriptional activation domains
to recruit nuclear coactivators that mediate chromatin
modiﬁcations and communication with the core promoters
[73].
Several lines of evidence indicated that activated PPARγ
crosstalks with cytokine-mediated signal transduction path-
ways in modulation of immune responses and tumor cell
growth and apoptosis [75–82]. Interestingly, in the case
of interactions between PPARγ and STAT3 [83–87], two
structurally distinct PPARγ ligands suppress IL-6 activated-
STAT3 through the divergent types of crosstalk including
direct or a corepressor SMRT-mediated association (see
Figure 1). The 15-d-PGJ2 is a naturally occurring ligand
with low aﬃnity of PPARγ, whereas a class of antidiabetic
drugs known as thiazolidinediones is a type of high-aﬃnity
synthetic ligands of PPARγ. Because the ligand-binding
pocket is not static, each PPARγ ligand has the potential to
induceadiﬀerentconformationofthereceptor.Additionally,
a non-PPARγ-dependent mechanism may be involved in
the diﬀerence between the eﬀects of 15-d-PGJ2 and the
thiazolidinediones on STAT3. Therefore, it is reasonable that
these two structurally distinct PPARγ agonists suppress IL-6
activatedSTAT3throughdiversemolecularmechanisms.The
multiplicity of crosstalk between nuclear receptors and other
transcriptionalfactorsisanimportantfactorthatcontributes
to both signal diversiﬁcation and speciﬁcation.
Direct protein-protein interaction between transcription
factors and ligand-activated nuclear receptors has been
shown involved in the regulation of some transcription
factors. In multiple myeloma cells, we demonstrated that
upon 15-d-PGJ2 binding, PPARγ indeed interacted with
phosphorylated STAT3 and represses IL-6 signaling by
inhibiting the binding of STAT3 to target genes [84].
Ligand-induced activation of PPARγ induces growth arrest
by antagonizing the prosurvival signaling cascade induced
by IL-6. PPARγ impedes IL-6 signaling by inhibiting the
transcription of a number of STAT3-regulated genes such
as mcl-1 and c-myc that are important in cell growth
and survival. The exact mechanism through which PPARγ
represses STAT3 has not been fully elucidated. PPARγ has
been shown to physically associate with STAT3, which
may inhibit STAT3 from binding DNA or possibly facil-
itate the export of STAT3 out of the nucleus. However,
certain agonists that induced growth arrests of these
cells did not induce SMRT to dissociate from PPARγ,
suggesting that this nuclear hormone receptor may use
numerous mechanisms to inhibit multiple myeloma cell
growth.
An alternative mechanism for PPARγ-mediated STAT3
repression has also been suggested, in which PPARγ agonist
treatment of multiple myeloma cells induces the corepressor
protein SMRT to dissociate from PPARγ; SMRT could then
complex with and inhibit the transcriptional activities of
STAT3. The corepressor SMRT has also to be demonstrated
to mediate PPARγ downregulation of STAT3 in multiple
myeloma cells. PPARγ can form weak interactions with
the corepressor NCoR/SMRT complex. PPARγ cannot bind
to DNA while it is associated with the corepressor com-
plex. After ligand binding, PPARγ disassociates from the
corepressor complex, and then binds to DNA through a
peroxisome proliferator response element. We ﬁrst clariﬁed
that treatment of MM cells with troglitazone decreased
association of SMRT with PPARγ, which results in redis-
tribution of corepressor SMRT from PPARγ to activated
STAT3. Furthermore, this interaction between SMRT and
IL-6-activated STAT3 can be attenuated by a PPARγ antag-
onist GW9662, conﬁrming the speciﬁcity of the exchange
of corepressor SMRT induced by the liganded PPARγ.
Recruitment of SMRT, which is associated with histone
deacetylase, by STAT3 leads to transcriptionally inactivating
STAT3 and consequently downregulating IL-6 mediated
MM cell growth and gene expression. These observations
supportthatcoactivatorsorcorepressorsfunctionisnotonly
for regulation of the ligand-dependent DNA binding and
transcriptional activities of nuclear receptors themselves but
also acts as a bridge protein to modulate nuclear receptors
crosstalk with other transcription factors.4 PPAR Research
Troglitazone
JAK JAK
15-d-PGJ2
IL-6
I
L
-
6
R
g
p
1
3
0
g
p
1
3
0
P P
P
P
P
P
P
P
P
P
P
STAT3 STAT3
STAT3 STAT3
STAT3STAT3 SMRT
SMRT
SBE
T
T
T
P
P
A
R
-
γ
P
P
A
R
-
γ
mcl-1
c-myc
Figure 1: PPARγ crosstalkwithIL-6-activatedSTAT3 signaling pathway. Upon IL-6 binding, the IL-6R/gp130 dimer induces phosphorylation
of JAK1,3, which in turn phosphorylates STAT3. The phosphorylated STAT3 dimerizes and translocates to the nucleues, where they bind
to the STAT3 binding element (SBE) in the responsive gene to initiate transcription. Two structurally distinct PPARγ agonists suppress IL-
6-activated STAT3 through diverse molecular mechanisms. 15-d-PGJ2 enhances direct physical protein-protein interaction between PPARγ
and phosphorylated STAT3 and represses IL-6 signaling by inhibiting the binding of STAT3 to target promoters; Troglitazone inhibits the
interaction between PPARγ and the corepressor SMRT, thereby inducing the redistribution of SMRT from PPARγ to activated STAT3, in
turn transcriptionally inactivating STAT3 signaling.
4. PPAR REGULATION OF CYTOKINE IN
IMMUNE CELLS
Theimmuneresponsecanbeclassiﬁedintotwofundamental
types: innate and adaptive immunity. The innate immune
response functions as the ﬁrst line of defense against
infection. It consists of soluble factors, such as complement
proteins, and diverse cellular components including granu-
locytes (basophils, eosinophils, and neutrophils), mast cells,
macrophages, dendritic cells, and natural killer cells. The
adaptiveimmuneresponseisslowertodevelopbutmanifests
as increased antigenic speciﬁcity and memory. It consists
of antibodies, B cells, and CD4+ and CD8+ Tl y m p h o c y t e s .
Natural killer T cells and γδT cells are cytotoxic lymphocytes
that straddle the interface of innate and adaptive immunity
[57]. In immune responses innate and adaptive immunity
are interlocked and complement each other.
Signaling in the immune system can be either a direct
interaction of cells or be mediated by cytokines and antibod-
ies that are carrying signals to all cells with the appropriate
receptors. Although PPARγ involvement in the regulation
of innate immunere sponses has been studied since the
late 1990s [16, 17], only recently it has the role of PPARγ
in adaptive immunity been investigated [18–32]. Here, we
focus on PPARγ regulation of cytokine-mediated immune
responses in immune cells.
4.1. PPARandIL-2
IL-2 is an autocrine and paracrine growth factor that is
secreted by activated T lymphocytes and is essential for
clonal T cell proliferation. Although originally described as a
potent T cell growth factor in vitro, the main nonredundant
role of IL-2 in vivo is now known to be the maintenance
of peripheral T cell tolerance. As well as promoting the
proliferation and survival of recently activated eﬀector T
cells, IL-2 also plays a critical role in regulatory T cell
(Treg) homeostasis and has been variously described as
promoting the thymic development, peripheral homeostasis
and suppressive function of Tregs. These observations,
stemming largely from studies on various murine models
of IL-2 and IL-2 receptor deﬁciency, have prompted a
greater understanding of the protolerogenic nature of IL-2
dependent signaling.
Greene et al. detected the expression of PPARγ2i n
normal neutrophils and peripheral blood lymphocytes in
1995 [9]. In human peripheral blood T cells, we detected
inhibition of PHA-induced proliferation and IL-2 produc-
tionby15-d-PGJ2 andTZDtroglitazoneinadose-dependent
manner [18]. When PPARγ2 wild type expression vector
was transfected into Jurkat cells, we found that troglitazone
and 15-d-PGJ2 inhibited transcription and production of IL-
2 in Jurkat cells in a PPARγ-dependent manner. Cotrans-
fection assays with PPARγ and PPRE-driven/IL-2 promoterXiao Yi Yang et al. 5
luciferase reporter constructs revealed that the inhibitory
eﬀects of troglitazone and 15-d-PGJ2 on IL-2 promoter
activity are dependent on the expression and activation
of PPARγ. Finally, we demonstrated that activated PPARγ
inhibited the DNA-binding and activity of transcription
factor NFAT regulating the IL-2 promoter in T cells.
Clark et al. described the expression and function of
PPARγ in mouse T-lymphocytes [20]. They demonstrated
that murine SJL-derived Th1 clones and freshly isolated T
cell-enriched splenocytes from SJL mice express PPARγ1
mRNA but not PPARγ2. To test its functional signiﬁcance,
they used two PPARγ ligands, 15-d-PGJ2 and a TZD,
ciglitazone. Both ligands could inhibit antigen-induced and
anti-CD3 antibody-induced T cell proliferative responses
of T cell clones, and the freshly isolated T cell enriched
splenocytes. In these studies, it was also demonstrated that
the two PPARγ ligands mediated inhibition of IL-2 secretion
by the T cell clones, whereas inhibition of IL-2 induced
proliferation was not detected.
4.2. PPARandIL-4
IL-4 is a pleiotropic and multifunctional cytokine produced
by activated T cells, mast cells, and basophils [88]. IL-
4 plays a critical role in regulating the outcome of an
immunere sponse by facilitating the diﬀerentiation of CD4+
T cells into IL-4-producing T helper (Th) type 2 cells and
suppressing the diﬀerentiation of interferon-γ producing
Th1 cells, thereby favoring humoral immune responses [89].
Regulation of IL-4 gene expression, therefore, is critically
important for the diﬀerentiation of Th2 cells and Th2-
dependent immune responses [90]. Dysregulated expression
of IL-4-producing cells has been linked with autoimmune
and allergic diseases [91].
In T cells, IL-4 gene expression is regulated at the tran-
scriptional level by both ubiquitous and cell type-restricted
factors, including NF-AT, c-Maf, GATA-3, STAT6, JunB,
and other transcription factors [90]. These factors interact
with a proximal promoter region composed of multiple
regulatory elements that can both positively and negatively
aﬀect transcriptional activation. IL-4 gene transcription is
mediated by subset-speciﬁc transcription factors such as
GATA-3 and c-Maf during the diﬀerentiation of naive T cells
into Th2 cells. A phase of short-term gene transcription,
elicited by the interaction of diﬀerentiated T cells with
antigen, requires the antigen-induced transcription factor
NFAT. Treatment of CD4+ T cells with ciglitazone or 15-d-
PGJ2 triggered the physical association between PPARγ and
NFATc1,resultinginIL-4promoterinhibitionanddecreased
IL-4 production [92].
Huangetal.[93]reportedthatIL-4inducesexpressionof
PPARγ and 12/15-lipoxygenase in macrophages, suggesting
the potential of coordinated induction of both receptor
and activating ligands. Therefore, it appears likely that
PPARγ is a key factor in regulating at least some aspects of
macrophage lipid metabolism and primarily as a repressor of
inﬂammatory responses. The ways how these two processes
are connected, and the contribution of macrophage speciﬁc
PPARγ-induced gene expression and transrepression to
inﬂammatory responses in vivo remains to be explored.
We reported an interesting PPARγ ligand-mediated
immunoregulatory circuit between monocyte/macrophages
and T cells [19]. Traditionally, T helper cells can be divided
into two functional subsets consisting of Th1 and Th2 cells
on the basis of the immunoregulatory cytokines that these
T cells produce. Some of these immunoregulatory cytokines
possess cross-regulatory properties and can enhance or sup-
presscytokineproductionbyTh1orTh2subset.Thpcellsare
the pluripotent precursors of Th1 and Th2 cells. Moreover,
the development of either Th1 or Th2 helper cells is believed
tobedeterminedbytheeﬀectsofcytokinesdirectlyonhelper
Thp cells. IL-4 is principally produced by helper T cells of
theTh2 phenotype. IL-4 has been shown to induce 12/15
lipoxygenase in monocytes/macrophages, which converts
arachidonic acid into several metabolic products, including
the potential PPARγ ligand 13-HODE [93]. Based on
this ﬁnding, we tested the relevance of the regulation of
soluble mediators (PPARγ ligands) released by IL-4 treated
monocytes/macrophages on T cell activation. The medium
of macrophages cultured with or without IL-4 was added to
T cells stimulated with anti-CD3 or PHA/PMA. We found
that T cells with the conditioned medium from IL-4-treated
macrophages produced signiﬁcantly less IL-2. The medium
of IL-4-treated macrophages contained a suﬃcient amount
of 13-HODE and anti-13-HODE antibody could neutralize
the inhibitory eﬀects of the IL-4-conditional medium on
T cell IL-2 production. Using human T lymphocytes and
the PPARγ-transfected Jurkat T cells, we demonstrated the
speciﬁc inhibition by 13-HODE of the transcription factors
NFAT and NF-κB, the IL-2 promoter reporter, and IL-2
production.TheseobservationsledustohypothesizethatIL-
4,producedbyTh2cells,mayindirectlyaﬀecttheproduction
ofIL-2byThporTh1helpercellsbyinducingtheproduction
of these potential PPARγ ligands by macrophage 12/15-
lipoxygenase, which in turn interferes with the subsequent
development of T helper cells (see Figure 2)[ 19].
Since many complicated pathological situations cannot
be simply explained by the Th1 cell and Th2 cell paradigm,
eﬀorts to resolve these issues in recent years have resulted
in the discovery of many new T helper cell subsets such as
Treg cell and Th17 cell subsets. Therefore, it is interesting to
explore further how PPARγ regulates these new Th subsets
(see Section 5).
4.3. PPARandIFNγ
IFNγ plays a central role in inﬂammatory reactions and is
predominately produced by CD4, CD8, and NK cells. IFNγ
drives inﬂammatory reactions by stimulating the release of
NO, TNF-α,a n dI L - 1 β bymonocytes/macrophages. IFNγ is
also a major eﬀector cytokine, responsible for driving cell-
mediated immunity and mediating organ-speciﬁc autoim-
munity. Recent studies have shown that PPARγ ligands
inhibit IFNγ production by T lymphocytes; however, the
mechanism underlying this observation has not been clar-
iﬁed [94]. Based on previous studies, PPARγ ligands could
indirectly decrease IFNγ by inhibiting activation of T cells,6 PPAR Research
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Figure 2: PPARγ regulation of cytokine-mediated immunoregulatory circuit between monocytes/macrophages and T lymphocytes. Th e l p e r(T h )
lymphocytes can be traditionally divided into two functional subsets consisting of Th1 and Th2 cells on the basis of the immunoregulatory
cytokines that these T cells produce. Thp cells are the pluripotent precursors of Th1 and Th2 cells. IL-4 is principally produced by helper
T cells of theTh2 phenotype. IL-4 can induce the upregulation of expression of the enzyme 12/15 lipoxygenase in monocytes/macrophages,
providing a potential PPARγ-speciﬁc ligands 13-HODE. The mediator secreted by monocytes can be taken up by neighboring Thp or Th1
cells and activate PPARγ in these cells. Since NFAT and NF-κB bind to the promoter region of the IL-2 gene and are needed to activate IL-2
transcription in T cells, the ligand-dependent binding of PPARγ to NFAT and NF-κB correlates the dissociation of NFAT and NF-κBf r o m
IL-2 promoter, thus inhibiting gene expression of IL-2 in Thp or Th1 cells.
production of IL-2, or induction of apoptosis, or inhibiting
IL-12 production by antigen-presenting cells [95–98].
Cunard et al. demonstrated that PPARγ is expressed
in both murine CD4 and CD8 cells and that PPARγ
ligands directly decrease IFNγ expression by murine and
transformed T cell lines. In contrast, GW9662, a PPARγ
antagonist, increases IFNγ expression. Transient transfection
studies reveal that PPARγ ligands, in a PPARγ-dependent
manner, potently repress an IFNγ promoter construct.
Repression localizes to the distal conserved sequence of
the minimal IFNγ promoter. They also demonstrate that
PPARγ acts on the minimal IFNγ promoter by interfering
with c-Jun activation. These studies suggest that many of
the observed anti-inﬂammatory eﬀects of PPARγ ligands
may be related to direct inhibition of IFNγ by PPARγ
[94].
5. PPAR REGULATION OF CYTOKINES IN TH17 AND
REGULATORY T CELLS
Recently, Th17 cells and CD4+ CD25+ regulatory T (Treg)
cells have been described as two distinct T helper cell
subsets from Th1 and Th2 cells. Th17 cells play critical
roles in the development of autoimmunity and allergic
reactions by producing IL-17 and, to a lesser extent, TNF-
α and IL-6 [99, 100], while Treg cells expressing the
forkhead/winged helix transcription factor (Foxp3) have
an anti-inﬂammatory role and maintain tolerance to self
components by contact-dependent suppression or releasing
anti-inﬂammatory cytokines [transforming growth factor
(TGF)-β1 and IL-10], therefore, the balance between Th17
and Treg may be important in the development/prevention
of inﬂammatory and autoimmune diseases [101, 102].
5.1. PPAR,IL-17andTh17cells
Production of IL-17 is a deﬁning feature of a recently identi-
ﬁed class of eﬀector T cells termed Th17 cells [99, 100]. Th17
cells act as a distinct eﬀector subset and secrete the signature
cytokineIL-17,aproinﬂammatorycytokinethatrecruitsand
activates neutrophils, enhances T cell priming, and promotes
the release of inﬂammatory mediators. Th17 cells provide
defense against extracellular bacteria, mediate inﬂammation,
and are critical for many types of autoinﬂammatory disor-
ders (i.e., experimental autoimmune encephalomyelitis, type
II collagen-induced arthritis, inﬂammatory bowel disease,
and psoriasis). The discovery and initial characterization of
these Th17 cells have provided a potential explanation forXiao Yi Yang et al. 7
various chronic disease pathologies that were unclear with
an understanding of only the Th1 and Th2 cell subsets.
IL-10-deﬁcient (IL-10-/-) mice spontaneously develop
inﬂammatory bowel disease with a Th1-polarized cytokine
pattern. In addition to showing high colonic expression of
the Th1-derived cytokine IFNγ,I L - 1 0 -/- mice also show high
expression of IL-17. Lytle et al. observed that rosiglitazone,
a high-aﬃnity ligand for PPARγ,h a di t sg r e a t e s te ﬀect in
suppressing IL-17 production in IL-10 knockout mice [103].
Interestingly, the PPARα ligand fenoﬁbrate has been shown
to repress IL-17 expression in cultured splenocytes activated
by PMA plus ionomycin and by Th17 cells in a pathogenic
CD4+ T cell line cultured from C3H Bir mice treated with
cecal bacterial antigens [104].
5.2. PPAR,TGFβandTregcells
At least two subtypes of CD4+ CD25+ regulatory T cells
(Tregs)havebeendescribed:thymicallyderivednaturalTregs
(nTregs) and inducible Tregs (iTregs) generated peripherally
from CD4+ CD25− Te ﬀector cells (Teﬀ)[ 100, 101].
Induced Treg are more functionally and phenotypically
heterogeneous in comparison to natural Treg and can be
subdivided into: induced Foxp3+ Tregs, Th3, and Tr1. Which
signals drive Treg cell proliferation in the tumor setting?
TGFβ is the cytokine that is thought to foster Treg-cell
ampliﬁcation [101]. Both tumor cells directly or “tumor
educated” immune cells can locally produce large amounts
of TGFβ [102]. Some mouse and rat tumors actively induce
myeloid immature dentritic cells to secrete TGFβ and this
promotes Treg cell proliferation. There is also substantial
evidence that indicates the involvement of TGFβ in Treg
cell conversion. Wohlfert et al. have used ciglitazone, a
synthetic PPARγ ligands, to characterize the relationship
between PPARγ ligands and both iTregs and nTregs. They
reported that ciglitazone-activated PPARγ enhances the
TGFβ-dependent conversion of naive T cells into Foxp3+-
induced Tregs in vitro, although the mechanism by which
PPARγ enhances Treg activity remains unknown [105].
Hontecillas and Bassaganya-Riera have used PPARγ deﬁcient
CD4+ cells obtained from tissue-speciﬁc PPARγ null mice
to investigate the role of endogenous PPARγ on Treg and
eﬀector CD4+ T cell function. They demonstrated that
only PPARγ-expressing Treg was able to completely prevent
inﬂammation induced by eﬀector cells of either genotype,
suggesting that PPARγ expression and/or activation by
endogenous agonists is required for optimal Treg function
[106].
6. PPAR REGULATION OF CYTOKINES IN
CANCER CELLS
Cytokines that are released in response to infection, inﬂam-
mation, and immunity can function to inhibit tumor
development and progression. Alternatively, cancer cells can
respond to host-derived cytokines that promote growth,
attenuate apotosis, and facilitate invasion and metastasis.
Proinﬂammatory cytokines implicated in carcinogenesis
include IL-1, IL-6, IL-15, colony stimulating factors, TNF-α,
and the macrophage migration inhibitory factor. A unique
immune response signature, consisting predominantly of
humoral cytokines, promotes metastasis in hepatocellular
carcinoma. Likewise, a signature consisting of 11 cytokine
genes in the lung environment predicted lymph node
metastasis and prognosis of lung adenocarcinoma with IL-8
and TNF-α as the top 2 genes for predicting prognosis. IL-
8 was originally described as a monocyte-derived neutrophil
chemotactic factor that speciﬁcally attracted neutrophils and
was renamed due to its multiple function. IL-8 can have
angiogenic activities in several cancers including nonsmall
cell lung cancer and can function as a positive autocrine
growth factor. Both TNF-α and IL-6 contributed to the
chemically induced skin tumors and lymphomas in mice.
Collectively, cytokines are considered as a linker between
inﬂammation and cancer [55–57].
A considerable amount of research has shown that
PPARγ ligands suppress the proliferation rates of many
types of cancer cells, particularly those derived from
liposarcoma, colon cancer, breast cancer, prostate cancer,
myeloid leukemia, glioblastoma, and many others. Various
in vitro studies have shown that treatment of many types
of cancer cells with TZD resulted in the induction of
cell diﬀerentiation or apoptosis as well as improvement
in levels of various markers for invasion and metastasis.
Furthermore, activation of PPARγ by glitazones inhibits
angiogenesis and neovascularization both in vitro and in
vivo and blocks the release of vascular endothelial growth
factor from smooth muscle cells [107, 108]. In addition to
the above direct antiproliferative and proapoptotic activities
on cancer cells, eﬀects of PPARs and their ligands in cancer
cells may function through inﬂuencing cytokine production
or cytokine-mediated signal transduction pathways. The
mechanisms are probably linked to: (1) PPAR ligands may
sensitize cancer cells to the antitumor eﬀects of cytokines
such as TNFα, (2) PPAR ligands may suppress production
of cytokines for tumor cell growth, and (3) PPAR ligands
may aﬀect tumor microenvironment by regulation of Treg
through inﬂuencing associated cytokines. A good example
is that PPARγ ligands suppress multiple myeloma through
inhibiting IL-6 and IL-6 activated signal pathway in both
PPARγ-dependent and -independent manner.
6.1. PPARandIL-6
Interleukin-6 (IL-6) is a cytokine with multiple biologic
activities on a variety of cells. IL-6 plays a major role in the
responsetoinjuryorinfectionandisinvolvedintheimmune
response, inﬂammation, and hematopoiesis. Its deregulation
impacts numerous disease states, including many types of
cancer. Consequently, modulating IL-6 may be an innovative
therapeutic strategy in several diseases. IL-6 is a pleiotropic
cytokine that is involved in the physiology of virtually every
organ system. Aberrant expression of this cytokine has been
implicated in diverse human illnesses, most notably inﬂam-
matory and autoimmune disorders, coronary artery and
neurologic disease, gestational problems, and neoplasms. In
cancer, high levels of circulating IL-6 are observed in almost
every type of tumor studied and predict a poor outcome.8 PPAR Research
Furthermore,elevatedIL-6levelsareassociatedstronglywith
several of the striking phenotypic features of cancer. Several
molecules have been developed recently that target the
biologic function of IL-6. Early results in the clinic suggest
that this strategy may have a signiﬁcant salutary impact on
diverse tumors. The ﬁeld of cytokine research has yielded
a deep understanding of the fundamental role of IL-6 and
its receptor in health and disease. Therapeutic targeting of
IL-6 and its receptor in cancer has strong biologic rationale,
and there is preliminary evidencesuggesting that targeting of
the IL-6 system may be beneﬁcial in the treatment of cancer
[109].
One of the most studied tumor types in relation to IL-
6 is multiple myeloma, a malignancy of diﬀerentiated B-
lymphocytes. Multiple myeloma is characterized by accumu-
lation of clonal plasma cells in the bone marrow, accounts
for10%ofallhematologiccancers,andremainsanincurable
hematological malignancy [110–112]. Recently, we investi-
gated how PPARγ ligands suppress IL-6 gene expression
through crosstalk between PPARγ and NF-κBo rb e t w e e n
PPARγ and C/EBPβ [86]. C/EBPβ and NF-κB bind to the
promoter region of the IL-6 gene, and their cooperation is
needed to activate IL-6 transcription. The nuclear receptor
PPARγ can be activated by troglitazone. Predominately, the
complex between C/EBPβ and troglitazone-bound PPARγ
leads to decreased DNA binding and transactivation of
C/EBPβ, inhibiting gene expression of IL-6. In addition,
PGC-1, a coactivator, is shared by both PPARγ and NF-
κB. After activation by ligands, ligand-bound PPARγ com-
petes for the limited amounts of PGC-1. Therefore, NF-κB
dissociates with PGC-1 and decreases NF-κB DNA-binding
and transactivation, leading to blocked IL-6 transcription.
In the case of 15-d-PGJ2 inhibition of IL-6 transcription,
although 15-d-PGJ2 also shares the above ligand-bound
PPARγ downregulation mechanisms on C/EBPβ and NF-
κB, 15-d-PGJ2, compared with troglitazone, prefers to use
PGC-1 as a bridging protein to associate with NF-κB. In
addition, 15-d-PGJ2 inactivates NF-κB through decreasing
phosphorylation of IKK and IκBi nP P A R γ-independent
manner.ThemolecularmechanismsofPPARγ ligandsonthe
regulation of multiple transcription factors have proven, not
surprisingly, complex. Given that IL-6 is the key growth and
survival factor of multiple myeloma cells, and is particularly
involved in the origin of all benign and malignant plasma
cell expansions as well as MM cell resistance, the eﬀects and
targets of the PPARγ ligands on aspects of multiple myeloma
biology and bone marrow stromal cells may be clinically
relevant.
7. CONCLUSIONS
Most proinﬂammatory cytokines produced by either
host immune cells or tumor cells themselves promote
tumor development. By contrast, proapoptotic and anti-
inﬂammatory cytokines usually interfere with tumor
development [55]. There is emerging evidence that the
n u c l e a rr e c e p t o rP P A R γ interacts with transcriptional
factors to modulate cytokine production and action in
immunity, inﬂammation, autoimmune diseases, and
tumors. PPARγ regulation may occur at the levels of gene
expression of cytokines themselves and their receptors
or cytokine-mediated signaling transduction pathways in
immune cells and cancer. The crosstalk between PPARs
and cytokine signaling pathways mediating inﬂammatory
eﬀects at the cellular level is also eﬀective to induce the
expression of PPAR genes. The molecular basis of this
interaction has remained elusive, despite the proposal of
several distinct mechanisms. One of the most important
mechanistic aspects is protein-protein interaction through
a direct or cofactor-mediated indirect manner. On the
basis of insights into the mechanisms on interaction
between these two distinct families of transcriptional factors
activated by diﬀerent signaling pathways, new targeting drug
design and/or therapeutic strategies will be discovered and
developed for treatment of cytokine-related diseases ranging
from inﬂammation to cancer.
ABBREVIATIONS
AF: Activation function
AP-1: Activation protein 1
C/EBP: CCAT/enhancer-binding protein
DBD: DNA binding domain
ER: Estrogen receptor
IFN: Interferon
IL: Interleukin
Jaks: Janus kinases
LBD: Ligand binding domain
MAPK: Mitogen-activated protein kinase
MM: Multiple myeloma
NcoR: Nuclear receptor corepressor
NFAT: Nuclear factor of activated T cells
NF-κB: Nuclear factor-kappa B
PPAR: Peroxisome proliferator-activated receptor
PPRE: PPAR response element
RAR: Retinoic acid receptor
RXR: Retinoid-X receptor
STAT: Signal transducer and activator of
transcription
SMRT: Silencing mediator of retinoid and thyroid
receptors
SRC: Steroid receptor coactivator
TGF: Transforming growth factor
Th: T helper cell
TNF: Tumor necrosis factor
Treg: Regulatory T cell
TZD: Thiazolidinedione.
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